Virology News and Research

Latest Virology News and Research

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.

14 Oct 2009

Do not underestimate the serious impact of the H1N1 virus, say researchers

A research team has warned medical experts in the Northern Hemisphere not to underestimate the serious impact of the H1N1 (Swine flu) virus with a new report showing that many patients who were critically ill with the virus required prolonged life support treatment with heart-lung machines.

14 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

New Ultra Sensitive facemasks to protect against seasonal and swine flu

BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and the novel H1N1 virus.

14 Oct 2009

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

Critical illness among Canadian patients with 2009 influenza A(H1N1) occurred rapidly after hospital admission, often in young adults, and was associated with severely low levels of oxygen in the blood, multi-system organ failure, a need for prolonged mechanical ventilation, and frequent use of rescue therapies, according to a study to appear in the November 4 issue of JAMA.

13 Oct 2009

New RNA repair and modification system in bacteria discovered

In new papers appearing this month in Science and the Proceedings of the National Academy of Sciences, University of Illinois biochemistry professor Raven H. Huang and his colleagues describe the first RNA repair system to be discovered in bacteria.

13 Oct 2009

Users can share interactive information on Humanpapilloma Virus anonymously

A new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Humanpapilloma Virus (HPV). "Fact Check: HPV" (www.hpvfactcheck.org) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers.

13 Oct 2009

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.

13 Oct 2009

Educational video on seasonal and H1N1 vaccines development

Will a four-minute educational video about a team of Air Force researchers investigating the H1N1 influenza virus go "viral" with middle- and high-school students?

12 Oct 2009

Fully insured members of AvMed Health to receive coverage for H1N1 flu administration fees

AvMed Health Plans announced that it will cover H1N1 flu administration fees for all of its fully insured members. Co-pays, co-insurance and deductibles will not apply for administration of the H1N1 vaccine even if they have a benefit plan that does not include immunizations.

12 Oct 2009

Low-, middle-income countries could receive donated H1N1 vaccine shipments by November, WHO says

About 100 low- and middle-income countries could receive donated shipments of the H1N1 (swine flu) vaccine as early as November, Marie-Paule Kieny, of the WHO, told journalists Monday, Agence France-Presse reports. "Dozens of millions of doses are being lined up following offers from pharmaceutical companies," including Sanofi-Aventis, GlaxoSmithKline and MedImmune, as well as a coalition of developed nations "that have pledged to release 10 percent of their vaccine purchases for poor nations," the news service writes (10/12).

12 Oct 2009

Some scientists question results of recent HIV vaccine clinical trial

Weeks after clinical trial results showed an experimental HIV vaccine offered some potential protection against the virus, "a second analysis of the $105 million study, not disclosed publicly, suggests the results may have been a fluke, according to AIDS scientists who have seen it," the Wall Street Journal reports.

12 Oct 2009

Even with early shortages, public is conflicted about getting the swine flu vaccine

A federal health official downplays risks from swine flu vaccine while the demand for the vaccine causes shortages.

12 Oct 2009

Office Depot teams up with Acme United to create flu kit

With the onset of the H1N1 virus, commonly known as the Swine Flu, more and more small businesses need to be prepared. That’s why Office Depot, a leading global provider of office products and services, is teaming up with Acme United to create the “Fight the Flu Kit.”

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Virology News and Research

Latest Virology News and Research

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Do not underestimate the serious impact of the H1N1 virus, say researchers

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

New Ultra Sensitive facemasks to protect against seasonal and swine flu

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

New RNA repair and modification system in bacteria discovered

Users can share interactive information on Humanpapilloma Virus anonymously

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

Educational video on seasonal and H1N1 vaccines development

Fully insured members of AvMed Health to receive coverage for H1N1 flu administration fees

Low-, middle-income countries could receive donated H1N1 vaccine shipments by November, WHO says

Some scientists question results of recent HIV vaccine clinical trial

Even with early shortages, public is conflicted about getting the swine flu vaccine

Office Depot teams up with Acme United to create flu kit

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Wake Forest University School of Medicine honours researchers

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

Presentations on efficacy of interferon to combat influenza

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Microplate-based assays in virology research eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging